Studying a New Drug for Leukemia After Stem Cell Transplant
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how a new drug called a menin inhibitor works in patients with acute myeloid leukemia (a blood cancer) who have relapsed after receiving a stem cell transplant. Researchers want to understand which patients benefit most by studying specific markers in their blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia with specific genetic mutations (NPM1 or KMT2A changes)
- Your leukemia came back after you received an allogeneic stem cell transplant (a transplant from a donor)
- You are 18 years old or older
- You are willing to sign an informed consent form agreeing to participate in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted pill (a menin inhibitor) taken after a stem cell transplant to help keep AML from coming back. It's for people with certain genetic markers in their leukemia who are already planning a transplant.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This trial tests a new treatment called NCR300 to see if it can prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It may help people who are at high risk of relapse.
This clinical trial tests a new menin-blocking drug called BN104 in combination with chemotherapy or other targeted drugs for people with acute myeloid leukemia (AML) that has certain genetic changes. It may be an option if your AML is newly diagnosed or if you've already tried a menin inhibitor and it didn't work well enough.
This trial tests a new approach to reduce the chance of leukemia or other blood cancers coming back after a stem cell transplant. It uses careful monitoring before the transplant to try to prevent relapse.
This study tests whether a medication called IFN-α can help prevent the blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancers who are at high risk of relapse.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.